Rifampicin Mono-Resistant Tuberculosis—A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control-Reference-Cited by-全球学者库

Rifampicin Mono-Resistant Tuberculosis—A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control

Published:2021-01-28 Issue:2 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Malenfant Jason H¹^ORCID,Brewer Timothy F²³

Affiliation:

1. Public Health & Preventive Medicine Program, UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA

2. Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA

3. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA

Abstract

Abstract Tuberculosis (TB) remains the leading cause of death by an infectious pathogen worldwide, and drug-resistant TB is a critical and rising obstacle to global control efforts. Most scientific studies and global TB efforts have focused on multidrug-resistant TB (MDR-TB), meaning isolates resistant to both isoniazid (INH) and rifampicin (RIF). Newer diagnostic tests are resulting in an increasing awareness of RIF-resistant TB in addition to MDR disease. To date, RIF resistance has been assumed to be synonymous with MDR-TB, but this approach may expose TB patients with RIF mono-resistance disease to unnecessarily long and toxic treatment regimens. We review what is currently known about RIF mono-resistant TB, its history and epidemiology, mechanisms of RIF resistance, available diagnostic techniques, treatment outcomes reported globally, and future directions for combatting this disease.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab018/36136999/ofab018.pdf

Reference79 articles.

1. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries;Espinal;JAMA,2000

2. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000;Santha;Int J Tuberc Lung Dis,2002

3. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru;Suárez;Lancet,2002

4. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru;Kawai;Am J Trop Med Hyg,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series;Open Forum Infectious Diseases;2023-11-01

2. Rifampisin Dirençli Mycobacterium tuberculosis Kompleks Suşları Üzerine Benzimidazolyum Tuzlarının Antimikobakteriyel Etkinliğinin Araştırılması;Kahramanmaraş Sütçü İmam Üniversitesi Tarım ve Doğa Dergisi;2023-08-25

3. Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis;Scientific Reports;2023-07-12

4. Seasonal Gene Profiling in Tuz Lake with Regard to Biogeochemical Cycling;Kahramanmaraş Sütçü İmam Üniversitesi Tarım ve Doğa Dergisi;2023-06-01

5. Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies;Expert Review of Anti-infective Therapy;2023-05-08